Prescribing efficiency of proton pump inhibitors in China : influence and future directions by Zeng, Wenjie et al.
Strathprints Institutional Repository
Zeng, Wenjie and Finlayson, Alexander E and Shankar, Sushma and de 
Bruyn, Winnie and Godman, Brian (2015) Prescribing efficiency of 
proton pump inhibitors in China : influence and future directions. BMC 
Health Services Research, 15 (11). ISSN 1472-6963 , 
http://dx.doi.org/10.1186/s12913-014-0638-6
This version is available at http://strathprints.strath.ac.uk/51259/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any  correspondence  concerning  this  service  should  be  sent  to  Strathprints  administrator: 
strathprints@strath.ac.uk
	


	





	
 	 

	











	

!
"#$##%&'#()#*+$#,+$&*%+&
-
./
0

))1

2
3




10
!!
4
4100
-

5
 .
1


5
6
5
6
14


 #,7(+&)&*

 8

 (%! ($#,

 % ($#,

 "''0'#$##%&'#()#*+$#,+$&*%+&
4
59.
:+	
 
:

 

0
 
2
59.

 
	 9



  
0
59.

59
.
:0
"'' 
'
''

;($#</
0	=
59


>
2 
9	9
2 

"''	
0'
' ',$:

: 
:



:	0
49	9
 


	"''	
0' 
'?'#$'	 
:

 (2015):
Prescribing efficiency of proton pump inhibitors in 
China: influence and future directions 
Wenjie Zeng1* 
* Corresponding author 
Email: wenwin99@sina.com 
Alexander E Finlayson2 
Email: alexanderfinlayson@gmail.com 
Sushma Shankar3 
Email: sshanko@googlemail.com 
Winnie de Bruyn4 
Email: w.f.debruijn@students.uu.nl 
Brian Godman5,6,7 
Email: Brian.Godman@ki.se 
1 School of Management, Chongqing Jiaotong University, No.66 Xuefu Road, 
1DQ¶DQ'LVWULFW&KRQJTLQJ&KLQD 
2 Green Templeton College, University of Oxford, Oxford, UK 
3 Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University 
of Oxford, Headington, Oxford OX3 9DU, UK 
4 Department of Pharmaceutical Sciences, Utrecht University, Utrecht, 
Netherlands 
5 Department of Laboratory Medicine, Division of Clinical Pharmacology, 
Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm SE-
141 86, Sweden 
6 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, Glasgow, UK 
7 Liverpool Health Economics Centre, Liverpool University, Chatham Street, 
Liverpool L69 7ZH, UK 
Abstract 
Background 
Pharmaceutical expenditure is currently rising by 16% per annum in China, greater in recent 
years. Initiatives to moderate growth include drug pricing regulations, essential medicine lists 
and encouraging generic prescribing. These are principally concentrated in hospitals, which 
currently account for over 80% of total pharmaceutical expenditure. However, no monitoring 
of prescribing and perverse incentives encouraging physicians and hospitals to profit from 
drug procurement encourages irrational prescribing. This includes greater utilisation of 
originators versus generics as well as injectables when cheaper oral equivalents are available. 
The objective of the paper is to assess changes in proton pump inhibitor (PPI) utilisation and 
expenditure in China as more generics become available including injectables. 
Methods 
Observational retrospective study of PPI utilisation and procured expenditure between 2004 
and 2013 in the largest teaching hospital in Chongqing District as representative of China. 
Results 
Appreciable increase in PPI utilisation during the study period rising 10.4 fold, with 
utilisation of generics rising faster than originators. Oral generics reached 84% of total oral 
preparations in 2013 (defined daily dose basis), with generic injectables 93% of total 
injectables by 2013. Injectables accounted for 42% of total PPI utilisations in 2008 and 2009 
before falling to below 30%. Procured pricHVIRURUDOSUHSDUDWLRQVUHGXFHGRYHUWLPHí
Generic oral omeprazole in 2010 was 87% below 2004 originator prices, mirroring reductions 
VHHQ LQ :HVWHUQ (XURSH ,QMHFWDEOH SULFHV DOVR GHFUHDVHG RYHU WLPH í +RZHYHU
injectables typically 4.3 to 6.8 fold more expensive than equivalent orals - highest for 
injectable lansoprazole at 13.4 to 18.0 fold. High utilisation of more expensive oral forms as 
well as injectables meant that PPI expenditure increased 10.1 fold during the study period. 
Lower use of injectables, and only oral generic omeprazole, would result in accumulated 
savings of CNY249.65 million, reducing total accumulated expenditure by 84%. 
Conclusions 
Encouraging to see high utilisation of generic PPIs and low prices for oral generics. However, 
considerable opportunities to enhance prescribing efficiency through greater use of oral 
generic omeprazole. 
Keywords 
Proton pump inhibitors, China, Drug utilisation, Generics, Health policies, Prices, Europe 
Background 
There is increasing scrutiny over pharmaceutical expenditure with growth rates averaging 
50% in real terms among OECD countries during the past decade [1]. This is driven by well-
known factors including changing demographics and new premium priced drugs [2,3]. This 
has resulted in a number of measures and initiatives across countries to moderate growth 
rates, including initiatives for both new and established medicines [4-7]. Reforms and 
initiatives for established drugs principally aim to enhance the utilisation of low cost generics 
versus originators and single sourced (patented) products in a class or related class where all 
products are seen as essentially therapeutically similar. Classes include the proton pump 
inhibitors (PPIs), statins and renin-angiotensin inhibitor drugs, with the latter including both 
angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) 
[7-12]. Efficiency savings can be substantial for these classes with prices of generics as low 
as 2% to 10% of pre-patent loss prices in some countries [13-15] .Considerable savings have 
also been achieved among low- and middle income countries from switching originators to 
the lowest-priced generic drugs [16-18]. 
China has also seen considerable increases in pharmaceutical expenditure, growing at over 
16% per annum during the past decade and over 35% per annum in recent years [18-21]. This 
growth is attributable to several factors including urbanization, ageing populations, expansion 
in medical insurance, improvements in living standards and the irrational use of drugs [18]. 
&KLQD¶V KHDOWKFDUH V\VWHP KDV DOVR H[SHULHQFHG D WUDQVLWLRQ IURP D SODQQHG HFRQRP\ WR D
market economy in recent years. Alongside this, the Chinese government has introduced 
different types of health insurance in recent years targeting different populations, with 
coverage reaching over 90% of the population by 2011 [20,22-24] although large disparities 
still exist [25]. The ultimate goal of the authorities in China is universal coverage by 2020 
[22-24,26]. As a result of increased coverage, healthcare expenditure increased from 3.5% to 
5% of GDP between 1995 and 2010, equating to a ten-fold increase in yearly per capita 
spending from US$ 21 to 220 [24]. This further increased to US$350 per year in 2011 [21]. 
Alongside this, the financial support from the Chinese government to public hospitals 
declined steadily in recent years from approximately 60% of hospital revenues in 1980s to 
8.2% by 2003. As a result, pharmaceutical expenditure in hospitals now accounts for 
approximately 40% to 50% of their total income [18,21,27-30], with hospitals necessarily 
using the revenue from drug dispensing for their sustainability [20,24,28,31]. This has caused 
much concern in China regarding difficulties with obtaining medical services and their high 
cost. 
Consequently, the authorities in China have introduced a number of measures in recent years 
WR KHOS PRGHUDWH WKLV JURZWK LQ DQ DWWHPSW WR UHGXFH SDWLHQWV¶ RXW-of-pocket burden 
expenditure especially for pharmaceuticals [18,19,24,25,32]. To date, these have principally 
concentrated on pharmaceutical prices and expenditure in hospitals since more than 80% of 
total pharmaceutical consumption is currently dispensed in public hospitals in China 
[18,19,33]. For state-priced products, i.e. mainly prescription medicines in the national 
medical insurance catalogue, the National Development and Reform Commission (NDRC) 
sets maximum retail prices (price caps); for province- or municipality-priced products (OTC 
in the national medical insurance catalogue or medicines supplemented in the local insurance 
catalogue), the price management department determines the retail prices; and for all other 
products the retail prices are determined by the manufacturers themselves [18,24,28,34]. For 
instance, the NDRC has implemented 28 price adjustments between 1997 and 2011 
[18,20,35,36]. Medicines in hospitals are subsequently subject to tenders in each province 
and municipality, with each hospital pharmacy having its own product list. This tendering 
process is typically organized by the health administrative department of the provincial 
government as well as for non-profit medical institutions at or above the county level. The 
tendering procurement cycle is typically once yearly and the winner is a mixture of those 
with higher quality, lower price or a mixture of these. Published studies have suggested these 
bidding processes reduced prices of essential medicines by 16.9% between 2009 and 2011 
[24]. However, there are no pricing policies for generics in China unlike measures across 
Europe, which has led to low prices in a number of countries [14,15,37-40]. 
Demand-VLGH PHDVXUHV WR FRQWDLQ SKDUPDFHXWLFDO H[SHQGLWXUH LQ &KLQD¶V KRVSLWDOV LQFOXGH
the development of an essential medicine list, clinical guidance and guidelines to enhance the 
rational use of medicines [19-21,24,29,41,42]. There were reforms in 2007 - WKHµ3UHVFULSWLRQ
0DQDJHPHQW2UGLQDQFH¶- specifying that prescriptions should be written by INN. However, 
to date there has been limited enforcement [18,28]. As a result, physicians still tend to write 
prescriptions with the generic (INN) name and simultaneously indicate the brand or 
manufacturer name; alternatively, drugs are listed with the corresponding brand name or 
PDQXIDFWXUHULQKRVSLWDOV¶,7V\VWHP>@ 
However, the current incentive system, as well as limited demand-side measures, have 
resulted in considerable irrationality in prescribing despite measures to improve this 
[24,28,34]. This is illustrated by continued appreciable use of injectable drugs in China when 
oral tablets are available as alternatives without the potential for serious complications, e.g. 
antibiotics and steroids [31,34,36,44], greater prescribing of more expensive antibiotics [45] 
as well as considerable prescribing of traditional Chinese medicines (TCMs) with limited 
data on their effectiveness and safety [46]. 
PPIs are seen as standard treatment for a number of conditions including symptomatic 
treatment of gastro-oesophageal reflux disease (GORD), Helicobacter pylori infections and 
associated peptic ulcer disease as well as the management of peptic ulcer bleeding and the 
prevention of recurrent bleeding from peptic ulceration [47]. PPIs are also available as both 
oral tablets and intravenous injections (IV) in China. Oral therapy is seen as highly effective 
[48], similar in effectiveness to IV PPIs at equivalent doses [49]. However, we are aware that 
there may be considerable use of injectable PPIs in China and that generic PPIs will be 
available at lower cost than originators. Consequently, the rationale for evaluating the PPIs in 
China is included in Table 1. 
Table 1 Rationale for the studying PPIs in China [13,14,20,21,36,47,50,51] 
Key Factors 7KHXWLOLVDWLRQRIDQWDFLGVDQGPHGLFLQHVWRSUHYHQWDQGWUHDWXOFHUVKDV
increased rapidly in recent years in China due to their effectiveness, similar to 
other countries 
7KHUHLVQRDSSUHFLDEOHGLIIHUHQFHWKHUDSHXWLFDOO\EHWZHHQWKHYDULRXV33,V
and between originator and generic PPIs (provided bioequivalence has been 
demonstrated) 
%HWZHHQDQGDUDQJHRIJHQHULF33,VZHUHLQFOXGHGLQKRVSLWDO
lists in China with a considerable number available for potential procurement 
,QMHFWDEOH33,VRULJLQDWRUDQGJHQHULFDUHDOVRDYDLODEOHDWFRQVLGHUDEO\
higher costs than oral equivalents, and limited medical justification for their 
routine use 
Opportunities WRHYDOXDWHJHQHULFSHQHWUDWLRQUDWHVDQGVDYLQJVYHUVXVRULJLQDWRUVIRUERWK
oral tablets and injectables 
WRFRPSDUHDQGFRQWUDVW33,XWLOLVDWLRQDQGexpenditure patterns in China with 
those seen among Western European countries, which already provide 
universal and comprehensive healthcare and where multiple policies have been 
successfully introduced to enhance the prescribing of low cost oral generic 
tablets versus originators or patented (single-sourced) PPIs. In the Netherlands, 
combined measures resulted in expenditure for PPIs in 2010 58% below 2000 
levels despite a 3-fold increase in utilisation, and in Scotland multiple measures 
resulted in expenditure on PPIs in 2010 56% below 2001 despite also a 3-fold 
increase in utilisation 
Consequently, the principal objective of this study is to assess changes in PPI utilisation and 
expenditure in China as more generic PPIs are incorporated into hospital procurement lists 
including injectable and orals. Secondary objectives include assessing price reductions for the 
PPIs over time, and comparing the findings with other generics in China as well as Europe. 
Subsequently, suggesting potential future measures that the authorities in China could 
consider as they strive for universal access. This will on the experiences in Europe as they 
continue to strive for universal coverage. 
Methods 
This was an observational retrospective study of prescriptions dispensed over a ten year 
period between 2004 and 2013 [52]. This methodology was chosen since multiple supply- 
and demand-side measures have been introduced during this period in China, some of which 
have been described in the Background, making it difficult to perform an interrupted time 
series analysis. In addition, an appreciable number of generic PPIs are now available in 
China, procured at different times. 
Typically for these types of drug utilisation analysis, data is obtained from health authority, 
health insurance or pharmacy databases [7,50,53,54]. However in China, most drug 
utilisation studies are performed with data from hospitals, including urban healthcare 
facilities with in-patient beds, as they incorporate both inpatient and outpatient data 
[18,31,55]. In addition, as mentioned, they account for 80% of total drugs currently dispensed 
in China [18,33]. This is in view of the convenience of hospital dispensing, physician 
recommendations, possibility of nonstandardized prescriptions and greater assurance of 
pharmaceutical quality in hospitals [28]. Thereby, hospital procurement data is currently the 
most appropriate source of drug utilisation and expenditure data in China [46]. 
&KRQJTLQJ LV D PXQLFLSDOLW\ GLUHFWO\ XQGHU &KLQD¶V FHQWUDO JRYHUQPHQW ZLWK D WRWDO
population of 28.8 million people (2010 census). In the urban district in Chongqing City, the 
main public general hospitals include three hospitals affiliated to the Third Military Medical 
University, two hospitals affiliated to Chongqing Medical University, and 10 municipal 
hospitals. Every hospital may include different generic drugs from different manufacturers, 
but with the same originator equivalents as there are only a limited number of originator 
manufacturers [18,56,57]. 
In view of these factors, we chose the largest hospital in Chongqing District to conduct our 
study. This is because it is one of the largest hospitals in Southwest China and is a typical 
health provider to the public, has a wide range of medicines available for prescribing, and can 
provide comprehensive datasets on both utilisation and expenditure. The dataset was obtained 
from the magazine company of China Pharmacy. The company is located in Chongqing and 
is able to collect detailed information of drug procurement from large hospitals in southwest 
China through co-operation with these public hospitals. The data contains all individual 
procurement information including product names, purchase dates, dosage forms, 
specifications, manufacturers, unit prices and volumes. This is an authoritative source for 
drug utilisation statistics in China, which is regularly audited [18,46,56]. 
Six PPIs were available for analysis between 2004 and 2013. These were omeprazole, 
lansoprazole, pantoprazole, rabeprazole, esomeprazole, and ilaprazole (ATC C09CA01 to 09, 
C09DA01 to 05, C09DX01 to 03) [58]. Originator and generic PPIs were procured at 
different times with, as mentioned, an appreciable number of generics typically available for 
procurement. Originator PPIs are referred to as products currently or previously possessing 
intellectual property (patent), most of which are manufactured by joint ventures in China 
founded by global pharmaceutical companies. Generic drugs are those produced by Chinese 
enterprises with local investment. Utilisation was measured in terms of Defined Daily Dose, 
ZLWK '''V GHILQHG DV µthe average maintenance dose of a drug when used in its major 
indication in adults¶ ZLWK WKLV PHDVXUH UHFRJQLVHG DV WKH LQWHUQDWLRQDO VWDQGDUG WR DVVHVV
utilisation patterns within and between countries [59]. 2012 DDDs were used in line with 
international guidance [59-61]. 
7KH &KLQHVH FXUUHQF\ 5HQPLQEL ³yuan´ &1< ZDV XVHG WR GHWHUPLQH H[SHQGLWXUH DQG
expenditure/ DDD for PPIs over time. These were not adjusted for inflation or deflation 
during this period as we wanted to compute actual changes over time as a result of the 
tendering process. This mirrors similar studies across Europe, especially where the tendency 
of authorities is to reduce medicine prices to keep pharmaceutical expenditure under control 
[5,7,39,50,53]. We have also not converted CNY data to either US$ or Euros during the 
course of the study as we did not want the pricing data influenced by currency fluctuations 
especially during the recent financial crises in Europe and the US. 
Results 
Utilisation (DDDs basis) and expenditure (CNY) were analysed over time including both 
generics and originators for both oral and injectable PPIs. 
Utilisation 
There was an appreciable increase in the prescribing of PPIs, rising 10.4 fold from just over 
242,000 DDDs in 2004 to 2.51 million in 2013 (Figure 1). The greatest increase (15.7 fold) 
was seen with the injectable PPIs. At one stage (2008 and 2009), injectable PPIs accounted 
for 42% of total PPI utilisation before falling to below 30% in recent years (Figure 1). 
Figure 1 Utilisation of oral and injectable PPIs (in DDDs) between 2004 and 2013 in the 
Chongqing hospital. 
Utilisation of oral generic PPIs grew at a faster rate than oral originators (Figure 1). As a 
result, the % of total oral generic PPIs grew from 64% in 2004 (DDD basis) to between 82% 
and 87% between 2007 and 2013. There was also greater growth for generic versus originator 
injectable PPIs, growing from 46% of total injectables in 2004 to 93% between 2011 and 
2013 (DDD based). 
The utilisation of all forms of lansoprazole (originator and generic, oral and injectable) grew 
28.4 fold during the course of the study compared with 13.3 fold for rabeprazole, 9.7 fold for 
pantoprazole and 3.1 fold for omeprazole. The growth of lansoprazole was especially strong 
after the launch of generic injectable lansoprazole in 2010 (Figure 2). The decline in the 
utilisation of pantoprazole from 2010 onwards was due to falling utilisation of generic 
injectable pantoprazole. Generic omeprazole had not been procured since July 2010, with the 
utilisation of generic injectable omeprazole declining from 2010 onwards, Both factors to the 
lower utilisation of omeprazole in recent years (Figure 2). 
Figure 2 Total utilisation of the different PPIs (all formulations) in the Chongqing 
hospital from 2004 to 2013. 
Expenditure 
Total PPI expenditure increased steadily during the study period, rising 10.1 fold from just 
over 5.6 million CNY in 2004 to 56.7million CNY in 2013. Growth in expenditure on 
injectable PPIs was greater than for oral PPIs, with expenditure on injectable PPIs increasing 
from 57% of total injectable PPI expenditure in 2004 to 71% to 74% between 2008 and 2013 
(Figure 3). There was a variable contribution of generic oral PPIs to total oral PPI 
expenditure (Figure 3), reaching a maximum of 80% in 2008. However, there was steady 
growth in the contribution of generic injectable PPIs to total expenditure on injectable PPIs, 
reaching between 90% and 91% of total injectable PPI expenditure between 2011 and 2013 
(Figure 3). 
Figure 3 Expenditure (CNY) of oral and injectable PPIs between 2004 and 2013 in the 
Chongqing hospital. 
The greatest increase in expenditure was observed with lansoprazole at approximately 160 
fold, least for omeprazole (1.8 fold) (Figure 4). This reflects increased utilisation of injectable 
lansoprazole in recent years (Figure 2), with injectable PPIs overall typically 4.2 to 6.8 fold 
more expensive (CNY/ DDD) than their equivalent oral formulations (Table 2). This 
difference is greater for injectable lansoprazole at 13.4 to 18.0 fold higher than the equivalent 
oral formulation between 2010 and 2013 (Table 2). 
Figure 4 Total expenditure (CNY) of the different PPIs (all formulations) in the 
Chongqing hospital from 2004 to 2013. 
Table 2 Procured expenditure/ DDD (CNY) for the different PPIs (generic and originator) in the Chongqing hospital from 2004 to 2013 
PPIs Dosage form 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 % change overtime 
Omeprazole Generic Oral 4.15 4.11 3.42 3.27 3.27 3.03 1.85    í 
Omeprazole Generic Injection 38.89 34.29 27.16 27.87 27.25 28.09 29.75 29.41 22.91 14.50 í 
Omeprazole Originator Oral 14.19 13.87 12.16 12.11 11.86 11.85 11.70 11.58 11.85 11.83 í 
Omeprazole Originator Injection 73.21 70.61 65.30 64.65 62.18 62.18 61.28 60.77 56.42 45.32 í 
Lansoprazole Generic Oral  9.92 8.33 7.69 7.79 8.10 8.21 6.88 5.74 5.17  
Lansoprazole Generic Injection       110.00 104.11 96.30 93.04  
Pantoprazole Generic Oral 9.86 9.68 8.91 8.44 8.64 8.81 8.83 7.54 6.10 5.22 í 
Pantoprazole Generic Injection 92.15 76.74 63.24 58.68 55.31 54.05 53.72 34.13 27.51 21.68 í 
Pantoprazole Originator Injection         109.67 108.69  
Rabeprazole Generic Oral 11.99 12.74 15.28 11.50 10.29 10.23 10.11 9.32 8.25 7.78 í 
Rabeprazole Originator Oral 33.94 33.15 30.59 31.50 30.37 30.37     í 
Esomeprazole Originator Oral 14.08 15.20 13.23 13.72 13.73 12.88 13.20 13.60 12.80 12.64 í 
Esomeprazole Originator Injection     93.00 93.00 93.00 93.00 91.65 90.65  
Ilaprazole Originator Oral       32.83 32.34 32.22 32.22  
Total oral  12.35 11.91 11.60 10.43 9.84 9.74 9.98 9.24 8.12 8.16 í 
Total injectable  68.81 64.56 50.97 49.18 41.22 40.84 42.54 47.39 53.07 55.40 í 
Differences between injectable and oral (fold)  5.6 5.4 4.4 4.7 4.2 4.2 4.3 5.1 6.5 6.8  
NB - % change over time typically refers to 2013 vs. 2004. However, this can vary depending when the different formulations were first procured. Blank cells mean no PPI available. Fold = 
times, e.g. total injectable PPIs in 2004 were 5.6 times more expensive per item than the equivalent oral preparations (DDD based). 
There were price reductions for the various PPI formulations over time (Table 2). Overall, 
SULFH UHGXFWLRQV ZHUH JUHDWHU IRU WKH RUDO IRUPXODWLRQV FRPELQHG í WKDQ IRU WKH
LQMHFWDEOHIRUPXODWLRQVFRPELQHGí+RZHYHUWKHSHUFHQWDJHUHGXFWLRQRYHUWLPHZDV
different between the different PPIs as well as their different formulations (Table 2). 
Generally the procured price reductions were greater for generic formulations of the various 
PPIs than for the originator formulations (Table 2). 
The procured price for generic oral omeprazole in 2010 was 87% below the originator price 
in 2004 (expenditure/ DDD), with the price of generic injectable omeprazole in 2013 80% 
below the 2004 originator price. Generic oral rabeprazole in 2013 was 77% below 2004 
originator oral rabeprazole (Table 2). 
Discussion 
There was appreciable growth in the utilisation of both oral and injectable PPIs in the 
Chongqing district between 2004 and 2013, similar to the appreciable increase in the 
utilisation of oral PPIs among Western European countries during this period [13,14,50]. 
It was encouraging to see appreciable utilisation of generic oral PPIs, averaging over 80% of 
total PPIs on a DDD basis since 2007 (Figure 1). This is similar to the high rate of utilisation 
of generic vs. originator and patented (single-sourced) PPIs in the Netherlands, Scotland and 
Sweden [13,14,50]. The high utilisation of oral generic PPIs is enhanced by some originator 
companies not being part of hospital procurement process and/ or withdrawing from the 
hospital procurement, e.g. lansoprazole or pantoprazole (Table 2). However, there were no 
generic esomeprazole or ilaprazole during the study period (Table 2). This is in marked 
contrast to the situation seen with oral generic drugs for cardiovascular diseases in the 
Chongqing District including the ARBs and statins [18,46,56]. 
We believe these differences between the various product classes could be attributable to a 
number of reasons. Firstly, diseases of the cardiovascular system are seen as having greater 
importance in China compared with acid-related stomach disorders, and originator medicines 
are thought to have a more consistent effect in treating cardiovascular diseases than generics. 
Secondly, there are few local traditional Chinese medicines to treat peptic ulcer diseases 
unlike cardiovascular and cerebrovascular diseases [46]; consequently, domestic generic oral 
manufacturers have less competition. Lastly, it is believed some physicians think that 
doubling the dose of oral generic PPIs could lead to the same effectiveness as the originators 
at the standard dose, and this is acceptable in this situation. This contrasts with concerns 
among physicians with doubling doses for pharmacological treatments for cardiovascular 
diseases. However, we cannot say this with certainty without further research. 
It was also encouraging to see the prices of generic oral PPIs reduce appreciably over time 
(Table 2). This is similar to the situation for generic simvastatin in China [57] as well as 
among Western European countries including the Netherlands, Sweden and the UK [13-15]. 
In addition, the procured price of generic omeprazole in 2010 was 87% below the 2004 
originator procurement prices, matching the price reductions seen among Western European 
countries for generic omeprazole [13-15] as well as generic simvastatin in China [57]. 
However, there was variable use of the different oral and injectable PPIs suggesting 
continued irrationality in prescribing. The most utilised PPI was rabeprazole (DDDs basis), 
which had the highest expenditure/DDD for both the originator (when procured) and the 
generic versus the other oral PPIs (Table 2). In addition, generic oral omeprazole disappeared 
from the procurement list since July 2010 and at the time of its disappearance it had the 
lowest procured price (Table 2). There was also growing use of premium priced 
esomeprazole and ilaprazole, once available (Figure 2 and Table 2). 
Furthermore, there was appreciable utilisation of injectable PPIs (Figure 2), reaching a 
maximum of 41% to 42% of total PPI utilisation (DDD based) between 2008 and 2010 before 
reducing to under 30% in 2013. This utilisation is considerably higher than the WHO 
guidelines for injections among developing countries [36,44], and appreciably higher than 
suggested limited use generally given the effectiveness of oral PPIs [49]. We believe this 
high utilisation is driven by considerably higher expenditure for injectable versus oral PPIs, 
averaging 4.3 to 6.8 fold or greater in recent years, especially lansoprazole injectable (Table 
2), given the pressure on hospitals and physicians to make money from drug dispensing 
discussed earlier. This hypothesis is endorsed by a recent study which showed more 
appropriate use of injectables in China versus oral tablets, in line with WHO 
recommendations, once the procurement incentives had been removed coupled with 
programmes to enhance the rational use of medicines [36]. 
Consequently, there appears to be considerable opportunities to enhance the efficient use of 
PPIs in China to conserve resources without compromising care. This includes enhancing the 
utilisation of low cost oral generics versus originators and existing single sourced products, 
e.g. esomeprazole and ilaprazole, as well as oral versus injectable PPIs. Restricting hospital 
procurement to just one oral PPI, i.e. generic omeprazole, following similar initiatives among 
(XURSHDQFRXQWULHVDQG UHJLRQVHJ WKHµ:LVH/LVW¶ LQ6WRFNKROP0HWURSROLWDQ+HDOWKFDUH
Region [62,63], and assuming its procured price in 2010 continued to the end of the study 
(Table 2) as well as limiting the utilisation of injectable generic PPIs to just 5% of total PPIs 
± generic omeprazole (cheapest) - at its procured price each year, would have saved an 
accumulated estimated CNY249.65 million for this hospital during the study period. This 
amounts to 84% of total accumulated PPI expenditure. 
However, future demand-side measures are likely to have only limited success unless the 
current incentives encouraging physicians and hospitals to prescribe and dispense premium 
priced products including injectables are addressed. This is already happening as seen with 
recent initiatives among rural populations and public primary care providers in China to 
improve patient coverage, improve the provision of community health organisations, as well 
as enhance the rational use of medicines, which includes a 0% mark-up for public primary 
care providers [36,46,64]. In addition, pilot studies of different methods across China 
including remunerating providers, separating revenues from expenditures as seen among 
urban community health centers in Beijing, Chengdu and Hangzhou, collective bidding as 
well as implementing standard clinical treatment pathways [20]. These initiatives must 
continue helping to further reduce the utilization of injectable PPIs over time, building on 
recent changes. 
2QFHWKHVHPHDVXUHVDUHXQGHUZD\LQWURGXFLQJFRQFHSWVVXFKDVWKHµ:LVH/LVW¶ZKLFKOLPLW
the prescribing of medicines in classes and disease areas to those with the most robust data on 
effectiveness and safety as well as available prices [62] throughout the hospitals in the 
Chongqing District, along with continuous medical education and strengthening of hospital 
DTCs, should further enhance the quality and efficiency of prescribing [63]. This could 
provide an example to other provinces and municipalities throughout China as they grapple 
with similar issues to improve the rationality and efficiency of their prescribing. This though 
will require strong leadership to achieve this, including instigating quality measures and 
involving prescribers [65]; however, the potential economic benefits are considerable. 
Finally, we acknowledge this research is subject to limitations. These include the fact that 
data collection was from just one region and one hospital. However, we believe these 
findings are generalizable to other drug classes and other hospitals in China based on the 
merits of our methodology as well as the realities of current regulations and tendering 
systems in China. We have also not looked at the appropriateness of prescribing for PPIs with 
growing concerns with their overprescribing [66]. There are also concerns with the side-
effects of long-term use, i.e. an increase in infection rates including hospital and community-
acquired pneumonia as well as osteoporosis, which can result in increased fracture rates [67-
71]. However, this is difficult without access to the patient records. 
Conclusions 
We believe we have demonstrated that despite recent measures there is still considerable 
irrationality in prescribing in China especially around the high utilisation of injectable PPIs. 
There are also considerable opportunities to conserve resources without compromising care. 
Proposed measures include initiatives to enhance the rational use of medicines building on 
current pilot programmes as well as programmes among primary healthcare institutions in 
China. 
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